Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $35.70.

Several equities research analysts recently commented on the company. TD Cowen initiated coverage on Viridian Therapeutics in a report on Monday, November 25th. They issued a "buy" rating for the company. Royal Bank of Canada increased their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company reissued an "equal weight" rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th.

Viridian Therapeutics Stock Up 1.1 %

Shares of NASDAQ VRDN traded up $0.22 during trading on Wednesday, reaching $19.43. The company had a trading volume of 843,371 shares, compared to its average volume of 1,255,226. The stock has a market cap of $1.54 billion, a PE ratio of -4.51 and a beta of 1.13. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12-month low of $11.40 and a 12-month high of $27.20. The business's 50-day moving average is $19.42 and its 200 day moving average is $19.40.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.08 million. As a group, equities analysts forecast that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company's stock worth $254,424,000 after purchasing an additional 1,610,130 shares in the last quarter. Novo Holdings A S boosted its holdings in Viridian Therapeutics by 19.3% in the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company's stock worth $54,259,000 after buying an additional 385,000 shares during the period. Geode Capital Management LLC increased its stake in Viridian Therapeutics by 5.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company's stock worth $33,979,000 after buying an additional 81,951 shares in the last quarter. Great Point Partners LLC raised its holdings in Viridian Therapeutics by 50.0% during the third quarter. Great Point Partners LLC now owns 750,000 shares of the company's stock valued at $17,062,000 after acquiring an additional 250,000 shares during the period. Finally, Walleye Capital LLC lifted its position in shares of Viridian Therapeutics by 30.1% in the third quarter. Walleye Capital LLC now owns 560,007 shares of the company's stock valued at $12,740,000 after acquiring an additional 129,411 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.